Our data suggest that the supplementation of TYK2/STAT4/PIM pathway-driven small molecule inhibitors to TKI treatments could be a novel therapeutic approach to treat AML and prevent disease relapse. This evidence concerns the gene TYK2 and acute myeloid leukemia.